Saturday, February 8, 2025

CATEGORY

CADTH

Canada Funds Rare Disease Registry Enhancements to Support Drug Evaluation

Key TakeawaysCanada’s Drug Agency has awarded funding to 18 rare disease registries to enhance data quality for regulatory and reimbursement support. The funding...

New Flexible Service Available Through Scientific Advice Program

Key TakeawaysDrug sponsors can now request a flexible, expedited service for scientific advice, with turnaround as fast as 4 weeks. The program offers...

Drug Sponsors Benefit from New Flexible Scientific Advice Service for Faster Trial Guidance and Cost Reduction

Key TakeawaysDrug sponsors can now access a flexible service through the Scientific Advice program, allowing them to receive critical feedback on pivotal trial...

First Time-Limited Reimbursement Recommendation Accelerates Cancer Treatment Access

Patients in Canada with advanced-stage lymphoma are now one step closer to accessing Epcoritamab (brand name Epkinly), the first drug to receive a time-limited...

Canada Releases Final Report on Appropriate Drug Use Strategy

The Government of Canada recently released the final report from the Canadian Drug Agency Transition Office’s (CDATO) Appropriate Use Advisory Committee on the appropriate...

Patient Access Enhanced: Canada Expands Rolling Review Pilot for New Drugs

Canada’s Drug Agency has announced a significant step forward in improving patient access to new drugs. This move aligns with the ambitious Target Zero...

Medication Appropriateness: Canada’s Drug Agency to Implement New Strategies for Safe and Effective Use

The Government of Canada released the final report from the Canadian Drug Agency Transition Office’s (CDATO) Appropriate Use Advisory Committee on the appropriate use...

Consultation on Newborn Screening Guidance Approaches

Canada's Drug Agency is currently seeking feedback on a discussion paper outlining proposed approaches to developing pan-Canadian guidance for newborn screening. This initiative, led...

Early Access to Promising Oncology Drugs: A Look at Canada’s Successful NOC/c Policy

Health Canada’s Notice of Compliance with Conditions (NOC/c) policy has proven effective in providing Canadians with faster access to new oncology drugs based on...

Enhancing Drug Assessments with Companion Diagnostics

Canada's Drug Agency (CDA) has initiated the first phase of improvements to its reimbursement review program, specifically addressing companion diagnostics and enhancing drug assessments.These...

CADTH to Include Societal Perspectives in Economic Assessments: Revolutionizing Drug Evaluations

The Canadian Agency for Drugs and Technologies in Health (CADTH) is venturing into a groundbreaking trial aimed at integrating societal perspectives into the economic...

CADTH Report Unveils New Technologies Revolutionizing Complex Pediatric Care and Highlights Key Systemic Challenges

The field of complex pediatric care is currently witnessing unprecedented changes, as it embraces new technologies and innovative approaches to healthcare delivery. A comprehensive...

Optimizing Laboratory Testing: CADTH and Choosing Wisely Canada Set New Standards

CADTH, in partnership with Choosing Wisely Canada, has established a temporary advisory group aimed at setting guidelines for the minimum retesting intervals for seven...

Canada Takes Bold Steps to Improve Drug Access and Sustainability

The Government of Canada is taking significant steps to enhance the country's pharmaceutical system and ensure Canadians have better drug access. High drug costs,...

Fresh Insights and Recommendations from CADTH on Emergency Department Overcrowding

CADTH (Canada's Drug and Health Technology Agency) has recently released an extensive body of evidence and guidance aimed at addressing the critical issue of...

Latest news